Skip to content
Sign in

ASD · NASDAQ · ETF

Defiance Autism Impact ETF (ASD) Price, Holdings & Fees

$461.22−0.26%−$1.19End-of-day price as of Oct 9, 2026

Defiance Autism Impact ETF (ASD) closed at $461.22 on Oct 9, 2026, down 0.26% from the previous close of $462.41.

Share price, past year

1Y +17.06%

52-week range $376.98 – $474.54. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$461.22
Sep 30, 2026$463.10
Aug 31, 2026$425.85
Jul 31, 2026$419.22
Jun 30, 2026$445.24
May 29, 2026$444.11
Apr 30, 2026$420.61
Mar 31, 2026$399.10
Feb 27, 2026$405.45
Jan 30, 2026$394.76
Dec 31, 2025$391.16
Nov 28, 2025$392.99
Oct 31, 2025$392.56

Key statistics

Expense ratio
0.79%
as of May 31, 2026
Net assets
$1.4M
as of Jun 30, 2026
Holdings
39
as of Jun 30, 2026
52-week range
$376.98 – $474.54

Defiance Autism Impact ETF's expense ratio is 0.79%: $79.00 a year on $10,000 invested.

Holdings

Defiance Autism Impact ETF held 39 investments worth $1.35M as of Jun 30, 2026. Its largest holding was Definium Therapeutics Inc, at 4.77% of the fund.

Defiance Autism Impact ETF largest holdings by share of net assets
#Holding% of fundValue
1Definium Therapeutics IncDFTX4.77%$64.44K
2Neuren Pharmaceuticals LtdNEU3.23%$30.28K
3LifeStance Health Group IncLFST3.04%$41.10K
4Otsuka Holdings Co Ltd2.95%$245.43
5Acadia Healthcare Co IncACHC2.90%$39.22K
6ACADIA Pharmaceuticals IncACAD2.89%$39.06K
7MapLight Therapeutics IncMPLT2.89%$38.99K
8AbbVie IncABBV2.72%$36.74K
9BrightSpring Health Services IBTSG2.70%$36.54K
10Revvity IncRVTY2.68%$36.27K
11Bright Horizons Family SolutioBFAM2.65%$35.87K
12Medicover AB2.63%$3.67K
13Ipsen SA2.60%$40.16K
14Sumitomo Pharma Co Ltd2.60%$215.94
15Johnson & JohnsonJNJ2.59%$35.05K
16Brainsway LtdBWAY2.58%$34.90K
17Pearson PLC2.56%$45.97K
18Anavex Life Sciences CorpAVXL2.53%$34.23K
19Novartis AG2.53%$42.41K
20Life Healthcare Group Holdings2.52%$2.08K
21BioMarin Pharmaceutical IncBMRN2.52%$33.99K
22KPJ Healthcare Bhd2.51%$8.33K
23Repligen CorpRGEN2.50%$33.84K
24Roche Holding AGROP2.50%$41.94K
25Supernus Pharmaceuticals IncSUPN2.50%$33.77K

Top 25 of 39 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.

What the fund owns

Defiance Autism Impact ETF holdings by asset type
Asset type% of fund
Stocks99.83%
Cash and short-term investments0.21%
Defiance Autism Impact ETF holdings by country, largest 10
Country% of fund
United States56.57%
Japan10.18%
Switzerland5.04%
United Kingdom5.02%
Israel4.93%
Australia3.23%
Sweden2.63%
France2.60%
South Africa2.52%
Malaysia2.51%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the month to Jun 30, 2026, Defiance Autism Impact ETF's total return was +8.11%, as reported to the SEC.

Defiance Autism Impact ETF monthly total returns
MonthTotal return
Jun 30, 2026+8.11%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
Defiance Autism Impact ETF
Ticker
ASD
Exchange
NASDAQ
Fund type
ETF
Trust
ETF Series Solutions
SEC series ID
S000105084
SEC CIK
0001540305
Fractional shares
No

Recent SEC filings

Shareholder reports and prospectuses are filed by ETF Series Solutions, the trust behind Defiance Autism Impact ETF, and cover all of its funds.

Frequently asked questions

What is ASD's price?

Defiance Autism Impact ETF (ASD) closed at $461.22 on Oct 9, 2026, down 0.26% from the previous close of $462.41.

What is ASD's expense ratio?

Defiance Autism Impact ETF's expense ratio is 0.79%: $79.00 a year on $10,000 invested.

What does ASD hold?

Defiance Autism Impact ETF held 39 investments worth $1.35M as of Jun 30, 2026. Its largest holding was Definium Therapeutics Inc, at 4.77% of the fund. Its five largest holdings were Definium Therapeutics Inc, Neuren Pharmaceuticals Ltd, LifeStance Health Group Inc, Otsuka Holdings Co Ltd, Acadia Healthcare Co Inc.

How has ASD performed?

Over the month to Jun 30, 2026, Defiance Autism Impact ETF's total return was +8.11%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 28, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of May 31, 2026. Prices are generated sample data for development. Data sources and disclosures